Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1959 2
1960 1
1963 3
1965 1
1967 3
1968 3
1970 1
1971 3
1972 1
1973 1
1974 1
1977 3
1979 1
1981 1
1982 1
1983 1
1987 2
1988 1
1990 3
1992 4
1993 3
1994 1
1995 2
1996 2
1997 2
1998 2
1999 2
2000 2
2001 1
2002 2
2003 5
2004 2
2005 4
2006 5
2007 8
2008 5
2009 2
2010 5
2011 4
2012 2
2013 8
2014 10
2015 10
2016 7
2017 11
2018 12
2019 15
2020 32
2021 25
2022 28
2023 8

Text availability

Article attribute

Article type

Publication date

Search Results

226 results

Results by year

Filters applied: . Clear all
Page 1
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
Blauvelt A, Leonardi C, Elewski B, Crowley JJ, Guenther LC, Gooderham M, Langley RG, Vender R, Pinter A, Griffiths CEM, Tada Y, Elmaraghy H, Lima RG, Gallo G, Renda L, Burge R, Park SY, Zhu B, Papp K; IXORA-R Study Group. Blauvelt A, et al. Among authors: burge r. Br J Dermatol. 2021 Jun;184(6):1047-1058. doi: 10.1111/bjd.19509. Epub 2020 Oct 25. Br J Dermatol. 2021. PMID: 32880909 Free PMC article. Clinical Trial.
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J; IXORA-R Study Group. Blauvelt A, et al. Among authors: burge r. Br J Dermatol. 2020 Jun;182(6):1348-1358. doi: 10.1111/bjd.18851. Epub 2020 Jan 15. Br J Dermatol. 2020. PMID: 31887225 Free PMC article. Clinical Trial.
Choroidal neuroendocrine neoplasia in a dog.
Lucyshyn DR, Knickelbein KE, Hollingsworth SR, Reilly CM, Brust KD, Visser LC, Burge R, Willcox JL, Maggs DJ. Lucyshyn DR, et al. Among authors: burge r. Vet Ophthalmol. 2021 May;24(3):301-307. doi: 10.1111/vop.12875. Epub 2021 Feb 22. Vet Ophthalmol. 2021. PMID: 33616294
Dual Coaxial Longitudinal Polarization Vortex Structures.
Man Z, Xi Z, Yuan X, Burge RE, Urbach HP. Man Z, et al. Among authors: burge re. Phys Rev Lett. 2020 Mar 13;124(10):103901. doi: 10.1103/PhysRevLett.124.103901. Phys Rev Lett. 2020. PMID: 32216411
Smoking and drinking: a review of the literature.
Bien TH, Burge R. Bien TH, et al. Among authors: burge r. Int J Addict. 1990 Dec;25(12):1429-54. doi: 10.3109/10826089009056229. Int J Addict. 1990. PMID: 2094682 Review.
Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis.
Hawkes JE, See K, Burge R, Strakbein S, McKean-Matthews M, Saure D, Gooderham M, Leonardi C. Hawkes JE, et al. Among authors: burge r. Dermatol Ther (Heidelb). 2021 Aug;11(4):1107-1118. doi: 10.1007/s13555-021-00548-2. Epub 2021 May 29. Dermatol Ther (Heidelb). 2021. PMID: 34050899 Free PMC article. Review.
226 results